Lexicon Pharmaceuticals CEO Lonnel Coats' 2018 pay jumps 41% to $3.1M
Lexicon Pharmaceuticals reports 2018 executive compensation
By ExecPay News
Published: March 19, 2021
Lexicon Pharmaceuticals reported fiscal year 2018 executive compensation information on March 19, 2021.
In 2018, seven executives at Lexicon Pharmaceuticals received on average a compensation package of $1.5M, a 9% increase compared to previous year.
Average pay of disclosed executives at Lexicon Pharmaceuticals
Lonnel Coats, Chief Executive Officer, received $3.1M in total, which increased by 41% compared to 2017. 44% of Coats' compensation, or $1.4M, was in option awards. Coats also received $402K in bonus, $634K in salary, $691K in stock awards, as well as $12K in other compensation.
For fiscal year 2018, the median employee pay was $195,778 at Lexicon Pharmaceuticals. Therefore, the ratio of Lonnel Coats' pay to the median employee pay was 16 to one.
Praveen Tyle, Executive Vice President, Research and Development, received a compensation package of $1.5M, which increased by 13% compared to previous year. 37% of the compensation package, or $542K, was in option awards.
Jeffrey L. Wade, Chief Financial Officer, earned $1.4M in 2018, a 16% increase compared to previous year.
Pablo Lapuerta, Chief Medical Officer, received $1.3M in 2018, which increases by 17% compared to 2017.
Alexander A. Santini, Executive Vice President and Chief Commercial Officer, earned $1.2M in 2018, a 15% increase compared to previous year.
Alan J. Main, Executive Vice President, Innovation and Chemical Sciences, received $1.2M in 2018.
Brian T. Crum, General Counsel, earned $780K in 2018.
Related executives
Brian Crum
Lexicon Pharmaceuticals
General Counsel
Alan Main
Lexicon Pharmaceuticals
Executive Vice President, Innovation and Chemical Sciences
Lonnel Coats
Lexicon Pharmaceuticals
Chief Executive Officer
Jeffrey Wade
Lexicon Pharmaceuticals
Chief Financial Officer
Pablo Lapuerta
Lexicon Pharmaceuticals
Chief Medical Officer
Alexander Santini
Lexicon Pharmaceuticals
Former Executive Vice President and Chief Commercial Officer
Praveen Tyle
Lexicon Pharmaceuticals
Executive Vice President, Research and Development
You may also like
Source: SEC filing on March 19, 2021.